# WuXi Biologics (Cayman) Inc. (WXIBF)

> Source: Nexqual · https://nexqual.com/WXIBF · data as of 2026-10-21 20:00 UTC · cite as "Nexqual, WuXi Biologics (Cayman) Inc. (WXIBF), nexqual.com/WXIBF" · informational, not investment advice.

**Price:** USD 6.45 (+1.42% on the day) · last close of Oct 21, 2026; US market closed, not a live price. Prev close 6.36 · day 6.45–6.45 · 52w 3.9–7.49 · market cap $26.6B · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y +18.7% vs S&P 500 +14.4%; 5Y -57.0% vs S&P 500 +77.0%.
- Next earnings: 2026-08-25, EPS estimate USD —, revenue estimate $0K.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +18.7% | -57.0% |
| S&P 500 (SPY) | +14.4% | +77.0% |
| Per year | +18.7% | -15.6% |
| Volatility (annualized) | 56.0% | 76.8% |
| Max drawdown | -28.7% (Oct 2026→Oct 2026) | -91.3% (Oct 2021→Aug 2024) |

## Peers (Biotechnology)
ROIV (Roivant Sciences Ltd.) USD 36.69 -2.03% · GMAB (Genmab A/S) USD 42.95 +7.38% · INCY (Incyte Corporation) USD 116.05 -0.75% · ALNY (Alnylam Pharmaceuticals, Inc.) USD 227.14 -0.06% · BNTX (BioNTech SE) USD 88.53 -1.28% · INSM (Insmed Incorporated) USD 94.14 -0.97%

## More
Full page: https://nexqual.com/WXIBF · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | — | — | — | $25.69B | — |
| Next fiscal year (ends 2027-12-31) | — | — | — | $30.71B | — |